VETU (Derwent Veterinary Drug File)
SubjectCoverage

All developments and applications of veterinary drugs:• Analysis• Biochemistry• Chemistry• Endocrinology• Management• Microbiology• Pathology• Pharmacology• Zoology

File Type

BibliographicFeatures

Thesaurus

Controlled Term (/CT)

Alerts (SDIs)

Not available

CAS Registry
Number® IdentifiersPage Images

Keep & Share



SLART



Learning DatabaseStructures

RecordContent• Bibliographic information, Derwent's abstract and extension abstracts, controlled term
indexing and structure codes, as well as CAS Registry Numbers®, and Enzyme
Commission Numbers, where applicable.

File Size

75,796 citations

Coverage

1983-2001

Updates

Closed file

Language

EnglishDatabase
Producer

Clarivate
Friars House, 160 Friars Rd.
London SE1 8EZ
United Kingdom
Copyright Holder: Clarivate

September 2023

2VETU

Sources• 1,100 veterinary and scientific journals and conference proceedings.

User Aids• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE

Cluster• ALLBIB• AUTHORS• BIOSCIENCE• CORPSOURCE• TOXICOLOGYSTN Database Cluster information:
https://www.cas.org/support/training/stn/database-clusters

RelatedDatabases

VETB (data from 1968 to 1982)

September 2023

3VETU

Search and Display Field Codes
General Search Fields
Search Field Name

SearchCodeDisplay
Codes

Search Examples

Basic Index (contains single
words from title (TI), controlledterm (CT), abstract (AB) andextension abstract (ABEX), CAS
Registry Numbers (RN), andEnzyme Commission Number(EC) fields)

Noneor/BI

S EFFECT# OF NALOXONES FARM-ANIMAL(L)GONADOTROPIN-METAB?
S 465-65-6
S EC-1.16.3.1

AB, ABEX,EC, CT, RN,TI

Accession NumberAuthor
Availability of Document (1)(Reprint Address)
CAS Registry Number
Classification Code (1,2)(Profile Titles) (code and text)
Controlled Term (3,4)(limited by roles)/AN/AU/AV

S 1993-61315/AN
S PARVIZI N/AU
S INSTITUT TIERZUCHT NEUSTADT/AV

AN
AU
AV

/RN
/CC

CT, RNCC

Corporate Source (1)Derwent Drug Registry Name (5)(link to file DRUGR)
Document Type(code and text)
Entry Date (6)

/CS
/DDRN

S 465-65-6/RN
S 10/CCS NON-STEROID HORMONES/CCS MORPHINE-ANTAGONISTS/CTS MORPHINE-ANTAGONISTS *FT/CT(L)INJECTION *FT/CTS FDA DIV? SEAFOOD/CS
S 1967U81/DDRN/DT(or /TC)/ED(or /UP)
/EC/FA/ISNS JOURNAL/DT
S J/DTS L5 AND ED>19941020

DT

S EC-1.16.3.1/EC
S L7 AND MPC/FAS JRPFA4/ISN

CT, ECFA
SO/JT/LAS J REPROD FERTIL/JT
S L7 AND DE/LAS GERMAN/LA
S (BASLE OR BASEL)/LO
S 076 080 104 254/MPC
S 076 *G 080 *G 104 *G 254 *G/MPC
S 1991-1993/PY
S REPROD FERTIL/SOS JRPFA4/SO
S FOOD CHEM/SO(L)32 NO 3/SO
S G/SHS GALENICS/SHSOLAS EFFECT OF NALOXONE/TITI

Enzyme Commission Number
Field Availability
International Standard(Document) Number (CODEN)
Journal Title
Language(ISO code and text)
Location (1)Multipunch Code (7)(limited by roles)
Publication Year (6)Source (contains journal title,CODEN, collation)
Subject Heading (8)(Thematic Groups)(code and text)
Title/CT/LO/MPC/PY/SO/SH/TICT

CSCT

not displayed

LOMPCSOSOSH(1) Search with implied (S) proximity is available in this field.
(2) The 16 Profile Titles (/CC) were introduced in 1991.
(3) There are 9 roles available in field /CT to limit a search to a particular aspect of a drug or a disease: AE Adverse Effects, DI DrugInteractions, DM Drug Metabolism, FT Further Term (assigned when no other role assigned), OC Other Context, PH Pharmacology,
RC Reference Compound, RN Registry Name, TR Treatment.
(4) Controlled terms concerning the same drug in a record are linked by (L) proximity.
(5) For file crossover to file DRUGR, SELECT DDRN and search the resulting E-number(s) in DRUGR.
(6) Numeric search field that may be searched using numeric operators or ranges.
(7) Search with implied (L) proximity is available in this field. Multipunch codes concerning the same drug in a record are linked by (L)proximity.
(8) The 15 Thematic Groups (/SH) were used prior to 1991.

September 2023

4VETUThe Derwent Veterinary Drug File Thesaurus
Field

Relationshipcode/CTALL
AUTO (1)
BTHIE
NT
PFT
RT
TN
UF
USE

Content

ExamplesAll Associated Terms (BT, SELF, USE, UF, SEE,NEW, OLD, TN, EC, CN, RT, NT, NTE, ONTE)
Automatic Relationship (SELF, USE, UF, SEE, NEW,OLD, TN, EC, CN, NT, ONTE)
Broader Terms (BT, SELF, also BT1, BT2 etc.
possible)
Hierarchy (BT, SELF, NT)
Narrower Terms (SELF, NT, also NT1, NT2 etc.
possible
All Preferred and Forbidden Terms (SELF, USE, UF,SEE, SF, NEW, OLD, TN, EC, CN)
Related Terms (SELF, RT)
Trade Names (SELF, TN)
Preferred and Forbidden Terms (SELF, UF)
Forbidden and Preferred Terms (SELF, USE)E DACARBAZINE+ALL/CT
S DETICENE+AUTO/CT
E DACARBAZINE+BT/CT
E MITE+HIE/CT
E MITE+NT/CT
E DACARBAZINE+PFT/CT
E MINERALOCORTICOID+RT/CT
E DACARBAZINE+TN/CT
E DACARBAZINE+UF/CT
E DTIC+USE/CT(1) Automatic Relationship is SET OFF. In case of SET REL ON the result of EXPAND or SEARCH without any relationship code is thesame as described for AUTO.

DISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated byspaces or commas, e.g., D L1 1-5 TI CS. The fields are displayed or printed in the order requested.
Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC,and OCC formats.

FormatAB
ABEX
ANAUAVCCCS
CTDDRNDT (TC)EC
FA
ISN (1)
JT (1)LALO
MPC
PY (1)
RN (1)SHSO
TI

September 2023

Content
Abstract
Abstract Extension
Accession NumberAuthor
Availability of Document (Reprint Address)
Classification CodeCorporate Source
Controlled Term (incl. Enzyme Com. Nos. and CAS Registry Numbers)
Derwent Drug Registry Name
Document Type
Enzyme Commission Number
Field Availability
International Standard (Document) Number
Journal Title
Language
Location
Multipunch CodePublication Year
CAS Registry Number
Subject Heading
SourceTitle

ExamplesD TI AB 1-4
D ABEXDIS AND AU TI 1-10
D TI AV 1-5
D CC
D CS
D CT
D DCRND DT LAD EC
D AN FA
D JT ISN
D JT
D LA
D CS LO
D MPC
D PY
D RN
D SH
D SO
D TI 55VETUDISPLAY and PRINT Formats (cont'd)FormatContent

Examples

ABS
ALL
IALL
BIB
CBIB
IBIB
IND
MAX
TRIAL (TRI, SAM)

AN, AB, ABEX
AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, SH, CC, CT, FA
ALL, indented with text labels
AN, TI, AU, CS, LO, SO, AV, LA, DT, FA
AN, TI, AU, CS, LO, SO, AV, LA, DT (compressed bibliography)
BIB, indented with text labels
AN, SH, CC, CT, MPC
AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, ABEX, SH, CC, CT, MPC, FA
AN, TI, CC, CT

D ABS
D ALL
D IALLD BIB
D CBIBD IBIB
D IND
D MAX
D TRIAL

HIT
KWIC
OCC

Hit term(s) and field(s)Up to 50 words before and after hit term(s) (KeyWord-In-Context)
Number of occurrences of hit term(s) and field(s) in which they occur

D HIT
D KWICD OCC(1) Custom display only.

SELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Abstract
Abstract Extension
Accession NumberAuthor
Availability of Document
CAS Registry NumberCitation
Classification CodeCODEN
Controlled TermCorporate Source
Derwent Crop Registry Name
Document Type
Enzyme Commission Number
Field Availability
International Standard (Document) Number
Journal Title
Language
Location
Multipunch CodeOccurrence Count of Hit Terms
Publication Year
SourceSubject Heading
Title

Field CodeAB
ABEX
AN
AU
AY
RN
CIT (RE)
CC
CODEN
CT
CS
DDRN
DT (TC)
EC
FA
ISN
JTLA
LO
MPC
OCC
PY
SO
SH
TI

ANALYZE/SELECT (1)

SORT

Y (2)
Y (2)
Y
Y
Y
Y
YY
N
Y
Y
Y
Y
YY
Y (3)
YY
Y
Y
NY
Y (4)
Y
Y (default)

NN
N
Y
YN
NYYNY
NYYY
NYYYNYYNY
Y(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HITTI.
(2) Appends /BI to the terms created by SELECT.
(3) Selects or analyzes CODEN and appends /ISN to the terms created by SELECT.
(4) Selects or analyzes CODEN and appends /SO to the terms created by SELECT.
September 2023

6VETUSample Records
DISPLAY MAXAN
2001-63368 VETU
TI
In vivo effect of a COX-2 selective and nonselective nonsteroidal
anti-inflammatory drug on gastric mucosal and synovial fluid
prostaglandin synthesis in dogs.
AUJones C J; Streppa H K; Budsberg S C
CSUniv.Georgia
LOAthens, Ga., USASO
Vet.Surg. (30, Number 5, 497, 2001)
AV
University of Georgia, Athens, GA, U.S.A.
LA
EnglishDT
JournalAB
The in-vivo activity of a known selective COX-2 inhibitor, meloxicam (MX),and a nonselective NSAID, aspirin (AS), on the gastric mucosa and synovial
fluid of dogs with osteoarthritis was investigated, and this activity wascorrelated with COX-1 and COX-2 inhibition in blood. The results showedthat LPS-stimulated PGE2 in blood and PGE2 in synovial fluid weresuppressed by both AS and MX, which is consistent with activity against
the COX-2 isoenzyme. AS, but not MX, suppressed PGE2 in the gastricmucosa and TXB2 in blood, which is consistent with activity against COX-1.
This in-vivo model confirms a beneficial effect of a COX-2 selective
inhibitor, MX, on PG inhibition in the synovial fluid, while sparing
gastric mucosal PG synthesis. (conference abstract: American College ofVeterinary Surgeons, 11th Annual Symposium, Chicago, Illinois, USA,
October, 2001).
ABEX 12 Dogs with unilateral osteoarthritis of the stifle were treated in acrossover design with AS or MX for 21 days with a 6-mth washout betweentreatments. PGE2 levels in LPS-stimulated whole blood, synovial fluid,
and endoscope gastric mucosal biopsies, and thromboxane B2 (TXB2) inserum were measured on days 0, 7 and 21 of each treatment period using
ELISA.
AS significantly suppressed PGE2 in blood, gastric mucosa andsynovial fluid, as well as TXB2 in serum on days 7 and 21. MX
significantly suppressed PGE2 in blood and synovial fluid on days 7 and21 but had no effect on TXB2 in serum or PGE2 in gastric mucosa. (CLW)CC
1 Anesthesia and Pharmacology
CT
OSTEOARTHRITIS *OC; JOINT-DISEASE *OC; IN-VIVO *FT; DOG *FT; GASTRIC*FT; MUCOSA *FT; SYNOVIAL *FT; FLUID *FT; PGE2 *FT;PROSTAGLANDIN-METAB. *FT; PROSTAGLANDIN-ANTAGONIST *FT;THROMBOXANE-ANTAGONIST *FT; ANTIINFLAMMATORY *FT; SMALL-ANIMAL *FT[01] ASPIRIN *PH; ASPIRIN *RN; CYCLOOXYGENASE-1-INHIBITOR *FT;CYCLOOXYGENASE-INHIBITOR *FT; PROSTAGLANDIN-ANTAGONIST *FT; ANALGESICS*FT; ANTIPYRETICS *FT; ANTIRHEUMATICS *FT; ANTIAGGREGANTS *FT;ANTIINFLAMMATORIES *FT; PH *FT[02] MELOXICAM *PH; MELOXICAM *RN; CYCLOOXYGENASE-2-INHIBITOR *FT;CYCLOOXYGENASE-INHIBITOR *FT; PROSTAGLANDIN-ANTAGONIST *FT;ANTIINFLAMMATORIES *FT; CYCLOOXYGENASE-INHIBITORS *FT;CYCLOOXYGENASE-2-INHIBITORS *FT; PH *FTFA
AB; LA; CT
In North America
CAS Customer Center:
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.
800-753-4227 (North America)
614-447-3731 (worldwide)
E-mail: help@cas.org
Internet: www.cas.org

In Europe
CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

Phone:

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org
Internet: www.stn-international.com

In Japan
JAICI (Japan Association forInternational Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan
Phone:+81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp

E-mail:September 2023